Display options
Share it on

J Korean Med Sci. 2013 Feb;28(2):261-7. doi: 10.3346/jkms.2013.28.2.261. Epub 2013 Jan 29.

Predictive value of conjointly examined IL-1ra, TNF-R I, TNF-R II, and RANTES in patients with primary glomerulonephritis.

Journal of Korean medical science

Rafał Zwiech

Affiliations

  1. Department of Kidney Transplantation, Medical University of ?ód?, ?ód?, Poland. [email protected]

PMID: 23400706 PMCID: PMC3565138 DOI: 10.3346/jkms.2013.28.2.261

Abstract

Interleukin-1 receptor antagonist (IL-1ra), tumor necrosis factor soluble receptors (sTNF-R) type I and II, and regulated upon activation, normal T-cell expressed and secreted (RANTES) play an important role in the modulation of primary glomerulonephritis (GN) course. The aim of the study was to assess whether pre-treatment measurements of IL-1ra, sTNF-R, and RANTES assessed conjointly may be useful as predicting factors in patients with GN. In 84 patients (45 males and 39 female) serum concentration (pg/mL) and urinary excretion (pg/mgCr) of cytokines were measured. After 12 months of therapy with steroids and cyclophosphamide the patients were divided into two subgroups: Responders (R) and Non-Responders (NR) according to the treatment results. The urinary IL-1ra, TNF-RI and RII were significantly higher in R than NR (1,732 vs 646 with P < 0.001, 13.1 vs 6.3 with P = 0.005, and 33.6 vs 14.4 with P = 0.012). The urinary RANTES excretion was increased in NR (79.6 vs 28.5; P < 0.001). The multivariable analysis showed that if conjointly assessed, only urinary IL-1ra, TNF-R I and R II, RANTES with 85% probability pointed the feature remission (R). In conclusion, the urinary excretion of IL-1ra, TNF-R I and R II, and RANTES examined conjointly are effective in predicting favorable response to immunosuppressive treatment in patients with GN.

Keywords: Immunosuppressive Treatment Outcomes; Interleukin-1 Receptor Antagonist; Primary Glomerulonephritis; RANTES; Receptors, Tumor Necrosis Factor

References

  1. Med Sci Monit. 2002 Jan;8(1):BR24-9 - PubMed
  2. Kidney Int. 2001 Mar;59(3):1052-8 - PubMed
  3. Pol J Pathol. 2007;58(2):65-71 - PubMed
  4. Maedica (Bucur). 2010 Jul;5(3):167-70 - PubMed
  5. Nephrol Dial Transplant. 2011 May;26(5):1563-9 - PubMed
  6. Pediatr Nephrol. 2005 Sep;20(9):1273-8 - PubMed
  7. Kidney Int. 1993 Feb;43(2):479-85 - PubMed
  8. Am J Pathol. 2004 Jun;164(6):1967-77 - PubMed
  9. Nephrol Dial Transplant. 2001 Jun;16(6):1163-9 - PubMed
  10. Am J Kidney Dis. 2003 Apr;41(4 Suppl 3):I-IV, S1-91 - PubMed
  11. Pol Arch Med Wewn. 2002 Mar;107(3):215-21 - PubMed
  12. Nephrol Dial Transplant. 2001 Mar;16(3):518-24 - PubMed
  13. Clin Exp Nephrol. 2008 Aug;12(4):264-269 - PubMed
  14. Am J Kidney Dis. 1997 Nov;30(5):693-702 - PubMed
  15. Kidney Int. 1993 Oct;44(4):795-804 - PubMed
  16. Kidney Int. 2000 Jan;57(1):147-58 - PubMed
  17. Nephrol Dial Transplant. 1998;13 Suppl 1:80-5 - PubMed
  18. Nephrol Dial Transplant. 2002 Mar;17(3):363-8 - PubMed
  19. Kidney Int. 2002 Oct;62(4):1264-76 - PubMed
  20. Pediatr Nephrol. 2010 Aug;25(8):1419-28 - PubMed
  21. Nephron. 1991;57(3):257-61 - PubMed
  22. Hypertens Res. 2009 Jan;32(1):3-107 - PubMed
  23. Nephrology (Carlton). 2011 May;16(4):440-5 - PubMed
  24. Nephrol Dial Transplant. 1998 Jan;13(1):7-9 - PubMed
  25. Pediatr Nephrol. 2011 Jun;26(6):881-92 - PubMed
  26. Kidney Int. 2007 Dec;72(12):1543-9 - PubMed

Substances

MeSH terms

Publication Types